Menu Search
Equities

Zydus Lifesciences Ltd

ZYDUSLIFE:NSI

Zydus Lifesciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)949.05
  • Today's Change7.75 / 0.82%
  • Shares traded295.55k
  • 1 Year change+47.83%
  • Beta0.4057
Data delayed at least 15 minutes, as of Nov 22 2024 10:23 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Zydus Lifesciences Ltd grew revenues 13.40% from 172.37bn to 195.47bn while net income improved 96.88% from 19.60bn to 38.60bn.
Gross margin71.43%
Net profit margin20.01%
Operating margin25.06%
Return on assets15.00%
Return on equity21.09%
Return on investment19.96%
More ▼

Cash flow in INRView more

In 2024, cash reserves at Zydus Lifesciences Ltd fell by 748.00m. However, the company earned 32.34bn from its operations for a Cash Flow Margin of 16.54%. In addition the company used 14.75bn on investing activities and also paid 18.10bn in financing cash flows.
Cash flow per share51.03
Price/Cash flow per share18.45
Book value per share216.89
Tangible book value per share135.38
More ▼

Balance sheet in INRView more

Zydus Lifesciences Ltd uses little debt in its capital structure as supported by a debt to capital ratio of 0.78%.
Current ratio2.27
Quick ratio1.58
Total debt/total equity0.0087
Total debt/total capital0.0078
More ▼

Growth rates in INR

Year on year, growth in dividends per share fell -50.00% while earnings per share excluding extraordinary items rose 95.97%. Additionally when measured on a five year annualized basis, dividend per share growth is below the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg)0.72%
Div growth rate (5 year)-3.04%
Payout ratio (TTM)7.06%
EPS growth(5 years)15.99
EPS (TTM) vs
TTM 1 year ago		52.73
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.